(CIX: WRAL30)  1,099.88  up arrow+1.36  (0.12 %)  Updated: 08:10 PM EDT, Jul 24 2014
(NQ: Apple)  97.03  down arrow-0.16  (-0.16 %)  Updated: 08:10 PM EDT, Jul 24 2014
(NY: QUINTILES)  54.84  down arrow-0.16  (-0.29 %)  Updated: 06:40 PM EDT, Jul 24 2014
(OP: BASF SE)  110.58  down arrow-2.01  (-1.79 %)  Updated: 08:10 PM EDT, Jul 24 2014
(NQ: BioCryst)  12.17  up arrow+0.05  (0.41 %)  Updated: 08:10 PM EDT, Jul 24 2014
(NQ: BioDelivery)  12.61  up arrow+0.13  (1.04 %)  Updated: 08:10 PM EDT, Jul 24 2014
(NQ: CEMP)  9.42  down arrow-0.15  (-1.57 %)  Updated: 08:10 PM EDT, Jul 24 2014
(NQ: Cisco Systems)  25.83  up arrow+0.15  (0.58 %)  Updated: 08:10 PM EDT, Jul 24 2014
(NQ: Cree)  48.55  down arrow-0.4  (-0.82 %)  Updated: 08:10 PM EDT, Jul 24 2014
(NQ: DARA)  1.41  down arrow-0.08  (-5.37 %)  Updated: 08:10 PM EDT, Jul 24 2014
(NY: EMC CORPORATION)  28.89  up arrow+0.14  (0.49 %)  Updated: 06:40 PM EDT, Jul 24 2014
(NQ: Extreme Networks)  4.95  up arrow+0.01  (0.2 %)  Updated: 08:10 PM EDT, Jul 24 2014
(NQ: FB)  74.98  up arrow+3.69  (5.18 %)  Updated: 08:10 PM EDT, Jul 24 2014
(NY: GLAXOSMITHKLINE)  50.08  up arrow+0.04  (0.08 %)  Updated: 06:40 PM EDT, Jul 24 2014
(NQ: GOOG)  593.35  down arrow-2.63  (-0.44 %)  Updated: 08:10 PM EDT, Jul 24 2014
(NY: IBM)  195.24  up arrow+1.61  (0.83 %)  Updated: 06:40 PM EDT, Jul 24 2014
(NY: LH)  106.10  up arrow+0.47  (0.45 %)  Updated: 06:40 PM EDT, Jul 24 2014
(OP: Lenovo Group)  27.88  up arrow+0.83  (3.07 %)  Updated: 08:10 PM EDT, Jul 24 2014
(NY: MRK)  58.21  up arrow+0.1  (0.17 %)  Updated: 06:40 PM EDT, Jul 24 2014
(NQ: Microsoft Corp)  44.40  down arrow-0.47  (-1.05 %)  Updated: 08:10 PM EDT, Jul 24 2014
(NQ: NTAP)  38.12  up arrow+0.19  (0.5 %)  Updated: 08:10 PM EDT, Jul 24 2014
(NY: NOVARTIS AG)  89.13  up arrow+0.11  (0.12 %)  Updated: 06:40 PM EDT, Jul 24 2014
(OP: Novozymes A/S)  50.63    (0 %)  Updated: 08:10 PM EDT, Jul 24 2014
(NY: PFIZER)  30.34  down arrow-0.05  (-0.16 %)  Updated: 06:40 PM EDT, Jul 24 2014
(NQ: Pozen)  7.92  down arrow-0.13  (-1.61 %)  Updated: 08:10 PM EDT, Jul 24 2014
(NY: RED HAT)  56.38  up arrow+0.5  (0.89 %)  Updated: 06:40 PM EDT, Jul 24 2014
(NQ: BBRY)  10.38  up arrow+0.55  (5.6 %)  Updated: 08:10 PM EDT, Jul 24 2014
(NQ: Salix)  132.26  down arrow-0.09  (-0.07 %)  Updated: 08:10 PM EDT, Jul 24 2014
(NQ: SQI)  15.23  up arrow+0.2  (1.33 %)  Updated: 08:10 PM EDT, Jul 24 2014

Posts tagged “Biotech & Life Science”

10:06 a.m. yesterday

GSK seeks regulator approval for malaria vaccine

Fighting malaria The experimental shot is the most advanced candidate vaccine for malaria but results from previous trials have been disappointing. Research published in 2012 showed the shot only reduced malaria cases by about 30 percent in babies aged six to 12 weeks, the target age for immunization.

3:32 p.m. Wednesday

Premium Lock Exclusive: Biotech Center doubles size of startup loans due to lack of private investment funding

Despite cuts in its own state funding, the North Carolina Biotechnology Center is doubling the size of loans it makes to early-stage life science companies. Why? Lack of private-sector capital, says Peter Ginsberg, the Center's vice president for business and technology development. WRAL TechWire Insiders can read the details in this exclusive interview.

N.C. Biotech Center  N.C. Biotech Center

Updated 10:23 a.m. Wednesday

GSK sales, earnings slump; shares drop 5%; growth forecast slashed

GSK's HQ in London       Drug giant GlaxoSmithKline, hurt in part by a 20 percent decline in sales in China where the company is under criminal investigation, reports revenues and earnings that missed analysts' expectations on Wednesday. GSK also reduced its growth forecast for 2014 from as much as 8 percent to "basically similar" to 2013 and says it can't estimate what the financial impact could be from the China case.

10:18 a.m. Wednesday

CEO on the state of GSK: 'We're making significant progress'

Even with sales and profits declining sharply from a year ago, a cut in a growth forecast for this year and continuing legal issues resulting from a criminal investigation in China, GSK's chief executive officer Andrew Witty puts a positive spin on the state of the company in a video interview.

Top execs discuss GSK earnings, strategy Top execs discuss GSK earnings, strategy

6:52 a.m. Wednesday

StubHub hacked; Viamet's new exec; LinkedIn's $175M buy; Cisco boosts Euro startups; 4K TVs boost LG

Bulldog In today's Bulldog wrapup of tech and life science news: StubHub is hacked; Viamet names chief development officer; LinkedIn makes an acquisition; Cisco takes entrepreneur program to Europe; and 4K TVs for World Cup boost LG.

6:50 a.m. Tuesday

Premium Lock Raleigh firm turns to scores of investors to drive female 'Viagra'

Drugs for women Sprout Pharmaceuticals has positioned its drug as the first female equivalent to Viagra. And the privately held firm has turned to scores of investors for financial help in driving the drug toward FDA approval.

Updated 3:45 p.m. Monday

Premium Lock Precision agriculture: Tech drives next big thing in farming

Farming continues to evolve, becoming even more high tech. The latest wave is called "precision agriculture," and it was the topic of the NC Ag Biotech Professional Forum at the NC Biotechnology Center, uses GPS guided, self-steering equipment, drones to monitor crops, precise, hyper-local weather reports, and the collection and analysis of data in real time for immediate action or strategic planning. WRAL TechWire Insider Allan Maurer has the exclusive details.

Precision agriculture research stations dot N.C. Precision agriculture research stations dot N.C.

6:51 a.m. Monday

Latest news on wearable medical devices, wireless growing pains, Facebook and muni broadband

Bulldog In the latest Bulldog roundup of life science and technology news: Wear your medicine; Wireless operators' growing pains; Facebook says if you like it, buy it; and Mr. Wheeler, tear down these walls.

Updated 6:22 a.m. Monday

Have news? Share it with WRAL TechWire

Contribute to WRALTechWire WRALTechWire is continuously expanding its content lineup, and we want you to participate. We are looking for news and analysis about all things tech and life science from people who know their business.

6:19 a.m. Monday

Your 48 WRAL TechWire headlines from last week

Week in review Some local websites run one or two tech stories per day. Others a few more but mixed with a variety of business news. At WRAL TechWire, tech and life science make up the menu with nearly 50 stories published over the last five business days. Here's a look back at technology, life science and other related news as reported in WRAL TechWire last week.

July 17

Salix wins FDA approval for drug to treat rare genetic disorder

Salix Raleigh-based Salix Pharmaceuticals has received FDA approval for a drug to treat a rare genetic disorder called hereditary angloedema.

Updated July 17

Startup says aloha to name after Hawaii protests; FDA-Pozen update; new Tantalus exec; Apple $400M ebook settlement; Novartis earnings; Visa's new system

Bulldog In today's Bulldog wrapup of life science and technology news: A L.A. company changes its name after protests in Hawaii; FDA accepts Pozen application; smart grid firm Tantalus in Raleigh names COO; Apple faces $400M ebook settlement; Novartis earnings; and Visa launches new online payment system.

Updated July 17

Premium Lock Morrisville-based TyraTech raises $6M, launches head lice product in Europe

TyraTech is rolling out its head lice product in the U.K. and is funding its European expansion with $6 million in new funding. The company, which moved to Morrisville in 2011, says the head lice market is a $150 million a year opportunity.

TyraTech's technology process TyraTech's technology process

July 17

Drug firm Merz moving HQ, 250 jobs to Raleigh from Greensboro

Merz bringing HQ, jobs to Raleigh Pharmaceutical company Merz North America is shifting its headquarters from Greensboro to Raleigh and consolidating other operations in the Triangle.

Updated July 16

Josh Hardy, treated with experimental Chimerix drug, is going home

Chimerix, the Durham-based drug company working on experimental medicine that could save the life of a seven-year-old Josh Hardy, was granted approval by the U.S. Food and Drug Administration to administer the drug to the boy in March. On Wednesday, his mother said he is doing well and going home.

Josh Hardy Josh Hardy

July 16

Agile Sciences lands $1.5M NIH grant for cystic fribosis therapy

Raleigh biotechnology company Agile Sciences has landed a $1.5 million National Institutes of Health grant to help develop its cystic fibrosis therapy derived from sea sponges.

Talking science at Agile Sciences Talking science at Agile Sciences

July 16

Cary-based CRO Ockham acquired by U.K. firm

Chiltern Ockham, a life science contract research organization based in Cary, has been acquired by London-based Chiltern, which also is a CRO.

July 16

Yahoo earnings fall; N.C. Solar Center's new name; Novartis-Google 'Glass' contacts; Cree expands; Sling's new devices

Bulldog In today's Bulldog wrapup of technology and life science news: Yahoo takes a hit; N.C. Solar Center gets a new name; Novartis teams with Google for "Glass" contacts; Cree adds space; Sling's new devices.

July 15

Life science startups can get funding insight through NC Biotech Center library

PitchBook Check out PitchBook: North Carolina's life science community now has a new way to glean inside information that might help with funding and business strategy.

July 15

GSK invests up to $25M in new drug manufacturing technology - in Pa., not N.C.

GlaxoSmithKline, which operates a huge drug manufacturing facility in Zebulon, is investing as much as $25 million to license a technology platform from a California firm as part of efforts to develop new drugs. But GSK isn't bringing the platform to N.C., at least initially.

GSK's R&D facility in RTP GSK's R&D facility in RTP

Techwire Inside Partners
The Skinny: A Blog by Rick Smith


Dr. Mike Walden
Tech economy
Frank Vinluan
Life science
Vivek Wadhwa